Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 17, 2013

View Archived Issues

German grant supports work at Dengue Vaccine Initiative

Novel glutamate transporter modulator has protective effects in neurological disease models

Bankruptcy court allows sale of Savient assets to Crealta Pharmaceuticals

Asahi Kasei Pharma presents promising phase I results for AK-106-001616

Ampio spins off sexual dysfunction business into new company

KW-2478 demonstrates clinical activity in relapsed and/or refractory multiple myeloma

Final phase I lymphoma results presented for antibody-drug conjugates from Genentech

Japanese researchers present new TNIK inhibitors for cancer

Bristol-Myers Squibb designs new nAChR agonists

Sunshine Lake Pharma presents new ALK and c-Met inhibitors

The University of North Carolina synthesizes novel anticancer agents

Astrazeneca reports topline results from phase III study of lesinurad in gout

New GR antagonists prepared by Concept Therapeutics

Galapagos selects preclinical candidate for cystic fibrosis program

PharmAthene's SparVax anthrax vaccine program placed on clinical hold

JRC-LAMP-vax demonstrates safety in phase I trials

Research grants awarded to three Karolinska Development portfolio companies

The Jerome Lejeune Foundation provides grants to four U.S. researchers

Emergent Biosolutions to acquire Cangene

Japanese collaboration announced for antibody biosimilar development in oncology

Alnylam begins phase II study of ALN-TTRsc for transthyretin-mediated amyloidosis

AcelRx and Grunenthal establish commercial collaboration for Zalviso in E.U.

Cubist reports phase III ceftolozane/tazobactam study results

Norgine and Innovacell sign licensing agreement for ICEF-15

HER2 companion diagnostic to identify breast cancer patients for targeted medicines

Targacept reports topline results from phase IIb study of TC-5619 for schizophrenia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...